[Prognosis and prognostic factor analysis XXXX ].

@entity43 @entity1 @entity41
OBJECTIVE: To investigate the prognosis change and prognostic factors of @entity43 in recent over twenty years. METHODS: One hundred and fourty @entity1 with @entity43 were analyzed. They were divided into two groups based on their operation time. 56 @entity1 operated before Jan. 1980 were included in the first group, and the other 84 @entity1 in the second group. Kaplan-Meier survival curves of the two groups were calculated, and Cox model was used to evaluate the prognostic factors of the disease at univariate and multivariate levels using SPSS and SURVCALC software. RESULTS: There was no pathological difference in between the two groups, but the @entity1 in the second group received more aggressive chemotherapy. The overall 1-, 2-, and 5-year survival rates were 61.2%, 32.1%, and 8.5%, respectively. In the first group they were 42.3%, 29.6% and 4.5% respectively and in the second group 69.3%, 36.2%, and 11.2% respectively. The prognosis of the @entity1 in the second group was better than that in the first group, P < 0.05. Univariate analysis revealed that stage, grade, @entity41 size and chemotherapy were significant predictors of @entity1 ' outcome. COX regression analysis identified that they were all independent prognostic factors. The @entity1 with advanced, low grade, @entity41 (> 2 cm) had poor prognosis. The prognosis of the @entity1 who received equal or more than four, especially six cycles combined chemotherapy was improved. CONCLUSION: The prognosis of the @entity1 with advanced @entity43 has improved in recent over 10 years, higher optimal cytoreductive rate and equal or more than six cycles combined chemotherapy are important measures for the better prognosis of advanced @entity43 .
